{"id":909164,"date":"2025-11-12T16:27:12","date_gmt":"2025-11-12T21:27:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2025\/"},"modified":"2025-11-12T16:27:12","modified_gmt":"2025-11-12T21:27:12","slug":"mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mdxhealth-reports-results-for-the-third-quarter-and-nine-month-period-ended-september-30-2025\/","title":{"rendered":"Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025"},"content":{"rendered":"
\n

\n Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025<\/strong>\n <\/p>\n

\n Q3 revenues increased by 18% to $27.4 million<\/i>
\n
\n Adjusted EBITDA profitability of $1.0 million for Q3<\/i>
\n
\n Acquisition of ExoDx business from Bio-Techne Corporation<\/i>
\n
\n Conference call with Q&A today at 4:30 PM ET \/ 22:30 CET<\/i>\n <\/p>\n

\n IRVINE, CA\u00a0<\/b>\u2013 November 12, 2025 (GlobeNewswire<\/u><\/a>) \u2013 MDxHealth SA\u00a0(NASDAQ: MDXH)\u00a0(the “Company” or “mdxhealth”),\u00a0a leading precision diagnostics company,\u00a0today announced its financial results for the three and nine-month period ended September 30, 2025.<\/p>\n

\n Michael K. McGarrity, CEO of mdxhealth, commented:<\/b>\u00a0\u201cWe are pleased to report another strong quarter of growth and operating execution for mdxhealth with 18% revenue growth for the quarter and 20% growth year-to-date, coupled with continued discipline on our operating expenses which were essentially flat on a quarterly and year-to-date basis despite extraordinary ExoDx transaction expenses.\u00a0\u00a0Furthermore, total use of cash in Q3 was less than $1 million.<\/p>\n

Strategically, the period was highlighted by the acquisition of Exosome Diagnostics from Bio-Techne on September 15th. We will continue to prioritize the integration of the combined business throughout the fourth quarter, including transitioning our Select mdx customers to ExoDx and cross training our direct sales organization, now expanded from 50 to 60 direct sales representatives. The expansion of our sales organization was informed by the significant cross-selling opportunity of our menu of ExoDx, Confirm mdx and GPS, identified through our diligence on the combined customer base. To maximize the capture of this compelling near-term opportunity, we have decided to suspend our germline product introduction, apply those commercial resources to ExoDx, Confirm and GPS, and re-evaluate the germline opportunity in 2026.\u00a0<\/p>\n

Despite the elimination of expected Germline revenue contribution in Q3 and Q4, we remain confident in reaffirming our full-year guidance of $108 million to $110 million and expect our Q4 and full year revenue growth to meet or exceed 20%.\u201d<\/p>\n

\n Key highlights for the third quarter of 2025:<\/b>\n <\/p>\n